SCHEDULE: Topline Capital Discloses 5.3% Stake in Cytek Biosciences

Topline Capital Management, LLC, along with Collin McBirney and Topline Capital Partners, LP, reported a 5.3% beneficial ownership stake in Cytek Biosciences, Inc.

Summary

• Topline Capital Management, LLC (TCM), Collin McBirney, and Topline Capital Partners, LP (TCP or the Fund) collectively reported beneficial ownership of 6,780,847 shares of Cytek Biosciences, Inc. common stock.
• This ownership represents 5.3% of Cytek Biosciences, Inc.'s outstanding common stock, based on 127,864,830 shares outstanding as of October 31, 2025.
• TCM and TCP hold sole voting and dispositive power over all 6,780,847 shares.
• Collin McBirney, as the member-manager of TCM, is deemed to share voting and dispositive power over the same 6,780,847 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Cytek Biosciences, Inc.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• Topline Capital Management, LLC, an investment adviser, and its related entities, disclosed a significant 5.3% beneficial ownership stake in Cytek Biosciences, Inc., which may be viewed by the market as a vote of confidence.

Negatives

• No negative information regarding Cytek Biosciences, Inc.'s operations or financial health was disclosed in this beneficial ownership filing.

Risks

• The reporting persons, including Topline Capital Management, LLC and Collin McBirney, expressly disclaim beneficial ownership as to the securities held by the Fund, except to the extent of their pecuniary interests therein, clarifying that the filing does not constitute an admission of beneficial ownership for any other purpose.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Cytek Biosciences, Inc.'s future performance or outlook.

Management Comments

• We certify that, to the best of our knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing reflects an institutional investor's decision to take a significant stake in Cytek Biosciences, Inc., a company operating in the biotechnology or life sciences sector. Such disclosures provide transparency into major ownership positions within the industry.

Stakeholder Impact

• Increased transparency for shareholders regarding significant institutional ownership in Cytek Biosciences, Inc.

Key Dates

Keywords

Cytek Biosciences, Topline Capital Management, beneficial ownership, Schedule 13G, institutional investment, common stock, CYTK